Ahmed S. A. Mady

Ahmed S. A. Mady

Auto-generated profile, based on publicly available information

Ahmed S. A. Mady

Dunad Therapeutics, 15 Necco Street, Boston, MA 02210, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2014 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
FAFardokht Abulwerdi
Fardokht Abulwerdi
CLChenzhong Liao
Chenzhong Liao
MLMeilan Liu
Meilan Liu
Asfar AzmiAsfar Azmi
Asfar Azmi
AAAmro Aboukameel
Amro Aboukameel
ZNZaneta Nikolovska-Coleska
Zaneta Nikolovska-Coleska
Using a high-throughput screening (HTS) approach, we have identified and validated several small-molecule Mcl-1 inhibitors (SMI). Here, we describe a novel selective Mcl-1 SMI inhibitor, 2 (UMI-77), developed by structure-based chemical modifications of the lead compound 1 (UMI-59). We have characterized the binding of UMI-77 to Mcl-1 by using complementary biochemical, biophysical, and computational methods and determined its antitumor activity against a panel of pancreatic cancer cells and an in vivo xenograft model. UMI-77 binds to the BH3-binding groove of Mcl-1 with Ki of 490 nmol/L, showing selectivity over other members of the antiapoptotic Bcl-2 family. UMI-77 inhibits cell growth and induces apoptosis in pancreatic cancer cells in a time- and dose-dependent manner, accompanied by cytochrome c release and caspase-3 activation. Coimmunoprecipitation experiments revealed that UMI-77 blocks the heterodimerization of Mcl-1/Bax and Mcl-1/Bak in cells, thus antagonizing the Mcl-1 function. The Bax/Bak-dependent induction of apoptosis was further confirmed using murine embryonic fibroblasts that are Bax- and Bak-deficient. In an in vivo BxPC-3 xenograft model, UMI-77 effectively inhibited tumor growth. Western blot analysis in tumor remnants revealed enhancement of proapoptotic markers and significant decrease of survivin. Collectively, these promising findings show the therapeutic potential of Mcl-1 inhibitors against pancreatic cancer and warrant further preclinical investigations. Mol Cancer Ther; 13(3); 565–75. ©2013 AACR.

1 September 2021 in Cancer Cell
Verified
Journal Article
Closed access
JGJoseph M. Gozgit
Joseph M. Gozgit
MVMelissa M. Vasbinder
Melissa M. Vasbinder
RARyan P. Abo
Ryan P. Abo
KKKaiko Kunii
Kaiko Kunii
KKKristy G. Kuplast-Barr
Kristy G. Kuplast-Barr
HKHeike Keilhack
Heike Keilhack

21 April 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
FAFardokht A. Abulwerdi
Fardokht A. Abulwerdi
CLChenzhong Liao
Chenzhong Liao
AMAhmed S. Mady
Ahmed S. Mady
JGJordan Gavin
Jordan Gavin
CSChenxi Shen
Chenxi Shen
ZNZaneta Nikolovska-Coleska
Zaneta Nikolovska-Coleska
Mcl-1, an antiapoptotic member of the Bcl-2 family of proteins, is a validated and attractive target for cancer therapy. Overexpression of Mcl-1 in many cancers results in disease progression and resistance to current chemotherapeutics. Utilizing high-throughput screening, compound 1 was identified as a selective Mcl-1 inhibitor and its binding to the BH3 binding groove of Mcl-1 was confirmed by several different, but complementary, biochemical and biophysical assays. Guided by structure-based drug design and supported by NMR experiments, comprehensive SAR studies were undertaken and a potent and selective inhibitor, compound 21, was designed which binds to Mcl-1 with a Ki of 180 nM. Biological characterization of 21 showed that it disrupts the interaction of endogenous Mcl-1 and biotinylated Noxa-BH3 peptide, causes cell death through a Bak/Bax-dependent mechanism, and selectively sensitizes Eμ-myc lymphomas overexpressing Mcl-1, but not Eμ-myc lymphoma cells overexpressing Bcl-2. Treatment of human leukemic cell lines with compound 21 resulted in cell death through activation of caspase-3 and induction of apoptosis.

23 June 2010 in Biopolymers
Verified
Journal Article
Open access
PDF file
OZOlga E. Zolova
Olga E. Zolova
AMAhmed S. A. Mady
Ahmed S. A. Mady
SGSylvie Garneau-Tsodikova
Sylvie Garneau-Tsodikova
The bisintercalator natural products are a family of nonribosomal peptides possessing a range of biological properties that include antiviral, antibiotic, and anticancer activities. The name bisintercalator is derived from the ability to directly bind to duplex DNA through two planar intercalating moieties. Although 19 members of this family of compounds have been identified over the past 50 years, the biosynthetic genes responsible for the formation of four of these molecules (thiocoraline, SW‐163, triostin A, and echinomycin) were identified only recently. This recent progress opens an avenue towards understanding how Nature produces these bisintercalating products and provides the potential to develop and identify novel potent analogous lead compounds for clinical applications. This review discusses the mode of action of bisintercalators and summarizes recent genetic and biochemical insights into their biosynthetic production, analog formation, and possible mechanisms by which resistance to these compounds is achieved by their producing organisms. © 2010 Wiley Periodicals, Inc. Biopolymers 93: 777–790, 2010.

15 June 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
WGWilliam Giblin
William Giblin
LBLauren Bringman-Rodenbarger
Lauren Bringman-Rodenbarger
AGAngela H. Guo
Angela H. Guo
SKSurinder Kumar
Surinder Kumar
AMAlexander C. Monovich
Alexander C. Monovich
DLDavid B. Lombard
David B. Lombard
Cutaneous melanoma remains the most lethal skin cancer, and ranks third among all malignancies in terms of years of life lost. Despite the advent of immune checkpoint and targeted therapies, only roughly half of patients with advanced melanoma achieve a durable remission. Sirtuin 5 (SIRT5) is a member of the sirtuin family of protein deacylases that regulates metabolism and other biological processes. Germline Sirt5 deficiency is associated with mild phenotypes in mice. Here we showed that SIRT5 was required for proliferation and survival across all cutaneous melanoma genotypes tested, as well as uveal melanoma, a genetically distinct melanoma subtype that arises in the eye and is incurable once metastatic. Likewise, SIRT5 was required for efficient tumor formation by melanoma xenografts and in an autochthonous mouse Braf Pten–driven melanoma model. Via metabolite and transcriptomic analyses, we found that SIRT5 was required to maintain histone acetylation and methylation levels in melanoma cells, thereby promoting proper gene expression. SIRT5-dependent genes notably included MITF, a key lineage-specific survival oncogene in melanoma, and the c-MYC proto-oncogene. SIRT5 may represent a druggable genotype-independent addiction in melanoma.

5 February 2019 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
QZQiang Zhang
Qiang Zhang
AMAhmed S A Mady
Ahmed S A Mady
YMYuanyuan Ma
Yuanyuan Ma
CRCaila Ryan
Caila Ryan
TLTheodore S Lawrence
Theodore S Lawrence
MMMeredith A Morgan
Meredith A Morgan
FBXW7, a classic tumor suppressor, is a substrate recognition subunit of the Skp1-cullin-F-box (SCF) ubiquitin ligase that targets oncoproteins for ubiquitination and degradation. We recently found that FBXW7 is recruited to DNA damage sites to facilitate nonhomologous end-joining (NHEJ). The detailed underlying molecular mechanism, however, remains elusive. Here we report that the WD40 domain of FBXW7, which is responsible for substrate binding and frequently mutated in human cancers, binds to poly(ADP-ribose) (PAR) immediately following DNA damage and mediates rapid recruitment of FBXW7 to DNA damage sites, whereas ATM-mediated FBXW7 phosphorylation promotes its retention at DNA damage sites. Cancer-associated arginine mutations in the WD40 domain (R465H, R479Q and R505C) abolish both FBXW7 interaction with PAR and recruitment to DNA damage sites, causing inhibition of XRCC4 polyubiquitination and NHEJ. Furthermore, inhibition or silencing of poly(ADP-ribose) polymerase 1 (PARP1) inhibits PAR-mediated recruitment of FBXW7 to the DNA damage sites. Taken together, our study demonstrates that the WD40 domain of FBXW7 is a novel PAR-binding motif that facilitates early recruitment of FBXW7 to DNA damage sites for subsequent NHEJ repair. Abrogation of this ability seen in cancer-derived FBXW7 mutations provides a molecular mechanism for defective DNA repair, eventually leading to genome instability.